explore -WSS

explore

author：knowledge 2025-09-29 22:47:18 - browse：16

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Arc Institute generative AI designs new CRISPR systems

explore

WSS

Solving academic medical centers' existential crisis

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

New rules on organ donation and transplantation 'will bring chaos'

Arc Institute generative AI designs new CRISPR systems

focus

explore

focus

Moonlake's readout produced a cash windfall. Risks remain

Helping hospitals and community health centers plan for resilience

Supreme Court strikes down use of affirmative action

Military medical care influenced by rank and race, new study finds

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How artificial intelligence is being used to detect, treat cancer

BioMarin wins approval for gene therapy to treat hemophilia A

With measles on the rise, a personal story of a devastating disease

Duchenne breakthrough therapy leaves behind pioneering families

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

leisure time

Providers still hesitate to prescribe buprenorphine, study finds

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

FDA official pushes for dedicated emerging pathogens team

Second House panel advances two

In new study, freeze

Case highlights the risks of experimental stem cell therapy

hotspot

knowledge

explore

hotspot